Cyxone investigates listing on Nasdaq Main Market Nordic Small Cap

Cyxone (publ), a Swedish biotech in autoimmune diseases, announce today that the company investigates a future listing on Nasdaq Main Market Nordic Small Cap. Cyxone is since 2016 listed on Nasdaq First North Growth Market.

A listing on Nasdaq Nordic Small Cap would provide conditions for improved liquidity in the share, increase the attention from international analysts, and for institutional investors to consider investing in Cyxone. The company is presently improving procedures and quality regarding the company’s information flow and activities.

Ola Skanung, interim CEO & CFO
Tel: +46 (0) 705 121 040

Adelgatan 21
211 22 Malmö

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50,



Documents & Links